21 december 2017: Klik voor dit artikel op de volgende link:
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Posted 17/12/2017 12:05:3117 december 2017: klik op de link voor het artikel of studierapport:
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of SeizureThe UPWARD Study
Posted 17/12/2017 11:56:3417 december 2017: klik op de link voor het artikel en volledige studierapport:
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of SeizureThe UPWARD Study
...Mammografie zorgt nauwelijks voor vermindering van risico op overlijden aan gevorderde borstkanker maar wel voor veel meer onnodige behandelingen door overdiagnose
Posted 09/12/2017 16:27:089 december 2017: Bron: BMJ 2017; 359 (Published 05 December 2017) Cite this as: BMJ 2017;359:j5224
Het bevolkingsonderzoek naar borstkanker met periodieke screening d.m.v. een mammografie gedurende een periode...
Vaccin MVA-Muc1-IL2 - TG4010 - bij niet-klein-cellige longkanker geeft bemoedigende resultaten. Recente fase II studie bevestigt goede resultaten
Posted 28/11/2009 14:14:16Helpt u ons aan 500 donateurs?
4 december 2017: In The Lancet werd in 2016 deze studie gepubliceerd: TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Conclusie: TG4010 plus chemotherapy seems to improve progression-free survival relative to placebo plus chemotherapy. These data support the clinical value of the TrPAL biomarker in this clinical setting; because the primary endpoint was met,...
Multiple myeloma: Mona kreeg in 2002 de diagnose vergevorderde ongeneeslijke multiple myeloma (Kahler) maar leeft nog steeds met alleen een gezonde leefstijl en niet toxische middelen en zonder chemo
Posted 04/12/2017 11:47:36Helpt u ons aan 500 donateurs?
4 december 2017: Bron: Chris Wark's website
In 2002 kreeg Mona te horen van de artsen dat ze een ongeneeslijk stadium van vergevorderde multiple myeloma had. Zij werd naar huis gestuurd om te overlijden. Mona accepteerde dat en sloot zich op in haar appartement, nam geen telefoon meer aan en wachtte in feite lijdzaam op de naderende dood. Een vriend van haar kon dit echter niet aanzien en stimuleerde Mona om...
Meta-analysis Shows Association of Minimal Residual Disease–Negative Status With Improved Survival in Multiple Myeloma
Posted 02/12/2017 11:45:362 december 2017: klik op de titels
Conclusions and Relevance Minimal residual disease-negative status after treatment for newly diagnosed MM is associated with long-term survival. These findings provide quantitative evidence to support the integration of MRD assessment as an end point in clinical trials of MM.
Traditionally considered a death sentence,...
ASCO 2017: I-SPY 2 Trial: Combination of Pembrolizumab Plus Standard Neoadjuvant Therapy in High-Risk Breast Cancer
Posted 02/12/2017 11:42:522 december 2017: klik op de titel
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Posted 02/12/2017 11:40:222 december 2017: klik op de titel
Conclusions
After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and...
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
Posted 02/12/2017 11:24:062 december 2017: klik op de titel:
Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer.
Inovio Pharmaceuticals is leading the study to evaluate its T-cell activating therapies INO-5401 and INO-9012 in combination with cemiplimab, a PD-1 inhibitor developed by Regeneron Pharmaceuticals.
INO-5401 is...
Men with localized prostate cancer were randomized to radical prostatectomy or observation to compare nonfatal health outcomes and long-term mortality. After 19.5 years of follow-up, the overall mortality rate and the disease-specific mortality rate were not significantly different between the two groups. Among men...